The scientific and ethical feasibility of immunity passports (Q100733072)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

2 references

17 October 2022

25 October 2022

The scientific and ethical feasibility of immunity passports (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

main subject

COVID-19

1 reference

documentation

1 reference

freedom of movement

1 reference

active immunity

1 reference

public health

1 reference

4

Julian Savulescu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

author name string

Rebecca C H Brown

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

Dominic Kelly

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

Dominic Wilkinson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

publication date

16 October 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

Lancet Infectious Diseases

22 October 2020

1 March 2021

2 references

17 October 2022

25 October 2022

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

17 October 2022

25 October 2022

Ten reasons why immunity passports are a bad idea

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

SARS-CoV-2 Vaccines: Status Report

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Seasonal coronavirus protective immunity is short-lasting

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

COVID-19 immunity passports and vaccination certificates: scientific, equitable, and legal challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

A serological assay to detect SARS-CoV-2 seroconversion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Humoral Immune Response to SARS-CoV-2 in Iceland

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

A human neutralizing antibody targets the receptor binding site of SARS-CoV-2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Genomic evidence for reinfection with SARS-CoV-2: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Coronavirus vaccine trials have delivered their first results - but their promise is still unclear

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

The time course of the immune response to experimental coronavirus infection of man.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Privileges and Immunity Certification During the COVID-19 Pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Using social and behavioural science to support COVID-19 pandemic response

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

COVID-19-a very visible pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Socioeconomic inequality of access to healthcare: Does choice explain the gradient?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Race, Socioeconomic Status, and Health-Care Access Disparities in Ovarian Cancer Treatment and Mortality: Systematic Review and Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

Waiting for Certainty on Covid-19 Antibody Tests - At What Cost?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2820%2930766-0

7 January 2021

10.1016/S1473-3099(20)30766-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33075284%20AND%20SRC:MED&resulttype=core&format=json

22 October 2020

PMC publication ID

7567527

0 references

1 reference